BioSpace News Archive

Eisai Inc. today announced the expansion of its leadership team to include Tricia Brooks as Vice President & Head of Office, Government Affairs and Policy.

Chinook Therapeutics, Inc. today announced the appointment of Charlotte Jones-Burton, M.D., M.S. as senior vice president of product development and strategy.

Lineage Cell Therapeutics, Inc. announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Virtual Oncology Conference, in a fireside chat hosted by Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at B. Riley Securities.

Waters Corporation announced the U.S. Food and Drug Administration’s Office of Regulatory Affairs has purchased Waters™ Empower™ Chromatography Data Software and NuGenesis™ Laboratory Management Software, expanding its deployment of Waters’ software to support its medical products testing operations across its five field science laboratories.

Arcturus Therapeutics Holdings Inc. today announced updated data from clinical development programs for ARCT-154 and ARCT-165.

Asher Biotherapeutics today announced the expansion of its executive leadership team with the appointments of Don O’Sullivan, Ph.D., M.B.A., as Chief Business Officer, James Cross, Ph.D., as Vice President, Regulatory Affairs and Florence Zhu, CPA, as Vice President, Finance.

ENDRA Life Sciences Inc., a pioneer of enhanced ultrasound technologies, announced it has received Institutional Review Board approval from China’s renowned Shanghai General Hospital, for the first clinical study of ENDRA’s Thermo Acoustic Enhanced UltraSound device to assess Non-Alcoholic Fatty Liver Disease in that market.

A viable treatment strategy involves reducing abnormal protein accumulation in the brain with gamma waves. However, studies validating its therapeutic effects using non-focused ultrasound with gamma entrainment are lacking.

Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis.

Karyopharm Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for eltanexor.